NATALIA GUILES: Open Payments
NPI 1164148722 · VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,597 in 51 payments from 20 companies in 2025. Trend: 2023 $132 · 2024 $1,447 · 2025 $1,597
Food & beverage: $1,565Education: $32
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 7 | $213 |
| Alnylam Pharmaceuticals Inc. | 4 | $206 |
| Kestra Medical Technology Services, Inc. | 1 | $182 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $167 |
| Merck Sharp & Dohme LLC | 4 | $130 |
| Novartis Pharmaceuticals Corporation | 6 | $120 |
| Inspire Medical Systems, Inc. | 2 | $102 |
| Actelion Pharmaceuticals US, Inc. | 4 | $88 |
| Lilly USA, LLC | 3 | $72 |
| GlaxoSmithKline, LLC. | 2 | $59 |
Products named: AMVUTTRA, CAMZYOS, Assure WCD, JARDIANCE, VERQUVO, INSPIRE, LEQVIO, TRELEGY ELLIPTA.
Industry payments across CA — which companies pay providers there.
